RX. BioSyent

BioSyent Named to the Growth List Ranking of Canada’s Fastest-Growing Companies for Eighth Consecutive Year

BioSyent Named to the Growth List Ranking of Canada’s Fastest-Growing Companies for Eighth Consecutive Year

MISSISSAUGA, Ontario, Oct. 15, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been included in the 32nd annual Growth List, the definitive ranking of Canada’s Fastest-Growing Companies by Canadian Business and Maclean’s. The Growth List (formerly the Growth 500) ranks Canadian companies based on five-year revenue growth. Results of the annual ranking are published in a special print issue of Canadian Business with Maclean’s magazine and online at CanadianBusiness.com and GrowthList.ca.

Based on a five-year revenue growth rate of 75% (2014 - 2019), BioSyent was named as one of Canada’s Fastest-Growing Companies on the 2020 Growth List. This is the eighth consecutive year that BioSyent has been included in this ranking.

“We are proud to be recognized for our top-line growth among Canada’s Fastest-Growing Companies for the eighth consecutive year,” commented René Goehrum, President and CEO of BioSyent. “We are also proud of BioSyent’s track record of delivering profitability along with this growth, with Q2 2020 marking the 40th consecutive profitable quarter for the Company.”

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit .

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty/hospital and international business units.

As of the date of this press release, the Company has 12,808,600 shares issued and outstanding.

For further information please contact:

Mr. René C. Goehrum

President and CEO

BioSyent Inc.

E-Mail:

Phone: 905-206-0013

Web:

EN
15/10/2020

Underlying

RX.BioSyent

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioSyent

 PRESS RELEASE
Free
RX. BIOSYENT

BioSyent Announces Launch of New FeraMAX® Pd Powder 15

BioSyent Announces Launch of New FeraMAX® Pd Powder 15 MISSISSAUGA, Ontario, Oct. 19, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX® Pd Powder 15 by its subsidiary, BioSyent Pharma Inc., in Canada. FeraMAX® Pd Powder 15 is the second product incorporating Polydextrose-Iron Complex (PDIC), a patented oral iron supplement delivery system. In November 2020, BioSyent Pharma Inc. launched FeraMAX® Pd Therapeutic 150, the first product using the PDIC formulation in Canada.    Together, these transitions to the p...

October 19, 2021 1 EN
 PRESS RELEASE
Free
RX. BIOSYENT

BioSyent annonce le lancement du nouveau FeraMAX (MD) Pd Poudre 15

BioSyent annonce le lancement du nouveau FeraMAX (MD) Pd Poudre 15 MISSISSAUGA, Ontario, 19 oct. 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent »,« la Société », Bourse de croissance TSX : RX) a le plaisir d’annoncer le lancement de FeraMAXMD Pd Poudre 15 par sa filiale, BioSyent Pharma Inc, au Canada. FeraMAXMD Pd Poudre 15 est le deuxième produit intégrant le complexe polydextrose-fer (CPDF), un système breveté de supplémentation en fer par voie orale. En novembre 2020, BioSyent Pharma Inc. a lancé FeraMAXMD Pd Thérapeutique 150, le premier produit utilisant la formulation CPDF au C...

October 19, 2021 1 EN
 PRESS RELEASE
Free
RX. BIOSYENT

BioSyent Releases Q2 and H1 2021 Financial Results

BioSyent Releases Q2 and H1 2021 Financial Results MISSISSAUGA, Ontario, Aug. 25, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2021. Key highlights include: Second quarter (Q2) 2021 Net Revenues of $7,289,254 increased by 53% versus Q2 2020First half (H1) 2021 Net Revenues of $14,709,143 increased by 36% versus H1 2020Record quarterly Canadian Pharmaceutical Net Revenues in Q2 2021 of $6,670,322 increased by 51% versus Q2 2020H1 2021 Canadian Pharmaceutical Net Revenues of $12,904,085...

August 25, 2021 1 EN
 PRESS RELEASE
Free
RX. BIOSYENT

BioSyent Signs Exclusive Technology Agreement

BioSyent Signs Exclusive Technology Agreement MISSISSAUGA, Ontario, July 13, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an agreement to license a unique technology application to support better treatment outcomes for patients with iron deficiencies in Canada and BioSyent’s international markets. “As a market leader in the treatment and prevention of iron deficiency and iron deficiency anemia with our FeraMAX® brand, we are familiar with the challenges that patients and their healt...

July 13, 2021 1 EN
 PRESS RELEASE
Free
RX. BIOSYENT

BioSyent Releases Financial Results for Q1 2021

BioSyent Releases Financial Results for Q1 2021 MISSISSAUGA, Ontario, May 27, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2021. Key highlights include: Record first quarter (Q1) 2021 Net Revenues of $7,419,889 increased by 22% versus Q1 2020Q1 2021 Canadian Pharmaceutical Net Revenues of $6,233,763 increased by 5% versus Q1 2020Q1 2021 International Pharmaceutical Net Revenues of $1,140,279 increased by 1,578% versus Q1 2020Q1 2021 EBITDA1 of $2,359,085 increased by 18% versus Q1 2020...

May 27, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch